—— 要投稿,上万维,轻松学术交流

严正声明

本站非期刊官网,非中介代理,
不向作者收取任何费用!
举报微信:13140028228 冯老师

态度公正、信息求实、投稿自助、使用免费
Clinical Drug Investigation《临床药物研究》
月刊 - 新西兰
  • Clinical Drug Investigation《临床药物研究》
  • SCIE外文期刊
  • 期发文量6
  • 国人占比11.11%
  • 知网外文库,维普目次
  • 投稿方式--官网投稿
  • 期刊属性

  • 中科分区:3区
    OA期刊:混合
  • 综述期刊:
    TOP期刊:
  • 期均国文:1
    环比增速:-100.00%
  • 期刊信息

  • 研究方向:医学-PHARMACOLOGY PHARMACY药学
  • 国际刊号:ISSN 1173-2563;EISSN 1179-1918
  • 期刊语言:英语
    出版地区:新西兰
  • 投稿网址:https://www.editorialmanager.com/cdia/
  • 电子邮箱:
  • 期刊官网:https://www.springer.com/journal/40261
  • 作者指南:
  • 出版商网址:http://www.adisonline.info
  • 出版地址:5 THE WAREHOUSE WAY, NORTHCOTE, NEW ZEALAND, AUCKLAND, 0627
  • 期刊简介:Clinical Drug Investigation《临床药物研究》(月刊). Clinical Drug Investigation provides rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs. The Journal includes: Clinical trials, outcomes research, clinical pharmacoeconomic studies and pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs. Clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice. Pharmacodynamic and pharmacokinetic studies in healthy volunteers in which significant implications for clinical prescribing are discussed. Studies focusing on the application of drug delivery technology in healthcare. Short communications and case study reports that meet the above criteria will also be considered.

  • 万维提示


  • 1、投稿方式:在线投稿。

    2、期刊网址:https://www.springer.com/journal/40261

    3、投稿网址:https://www.editorialmanager.com/cdia/

    4、官网邮箱:相关咨询邮箱如下。

    5、期刊刊期:月刊,一年出版12期。

    2022118日星期

                                  

     

    期刊相关咨询邮箱【官网信息】

     

    Contact the journal

    Submission-related enquiries

    Queries about submission issues, peer review process, or the status of your manuscript should be sent to Kiruthika Gunaselvam (kiruthika.gunaselvam@springernature.com).

    Production-related enquiries

    Queries about accepted manuscripts in production or post-publication corrections should be sent to Anburaj Sundaram (Anburaj.Sundaram@springer.com).

    Rights and Permissions enquiries

    For permission requests to reuse or reprint content, please follow the link ‘Rights and permissions’ on the relevant article page. For other queries, contact journalpermissions@springernature.com.

    Publication-related enquiries

    Queries related to journal publishing should be sent to Jasbir Singh (jasbir.singh@springer.com).

     

    投稿须知【官网信息】

     

    Clinical Drug Investigation

    Submission guidelines

    Instructions for Authors

    Please read these instructions in conjunction with the "Additional Information for Authors" document. This document, together with other useful submission documentation, can be found by following the "Important Information for Authors" link:

    Important Information for Authors

    Types of Papers

    Please note:

    The word counts given below do not include the abstract, references, figure legends or table captions.

    Review Article. Word count up to 8000. Provides an authoritative, balanced, comprehensive, fully referenced and critical review of the literature.

    Current Opinion. Word count approximately 1500 to 3000. Places an area in perspective given that it is of current international interest and a consensus has not yet been reached; therefore, the arguments presented may be controversial, but at the same time must be balanced and rational.

    Leading Article. Word count up to 4000. Provides a short, balanced overview of the current state of development of an emerging area.

    Systematic Review. Word count up to 10,000. Collates all empirical evidence that fits pre-specified eligibility criteria to answer a specific research question. It uses explicit, systematic methods that are selected with a view to minimizing bias, thus providing reliable findings from which conclusions can be drawn and decisions made. Please follow the reporting guidelines of PRISMA.

    Original Research. This should be submitted as an Original Research Article (word count up to 4000 plus any Electronic Supplementary Material), following the reporting guidelines of CONSORT for randomized controlled trials, and STROBE for purely observational studies Reports of studies that have investigated original approaches to clinical management but that are smaller in scale and, thus, may report pilot data warranting further investigation, may also be considered for publication; such articles should be submitted as Short Communications.

    Case Report. Word count up to 1800 with a short (up to 150 word) abstract. Case reports on new or unusual events in one or more patients that expand the knowledge about common disease states or provide significant information about drug efficacy, adverse reactions, or interactions will be considered.

    Letter to the Editor. Word count up to 1000. Comment on an article published recently in the journal; a response to the comments would normally be sought from the authors of the original article and published in the same issue, where possible.

    Editorial/Commentary. Word count up to 1500. A brief opinion piece on a current topic of high interest.

    Editorial Procedure

    Internal Review by Editorial Staff: The journal editor will perform an initial appraisal of each manuscript. If your paper has been peer reviewed by another journal as part of a prior submission, the journal editor will also assess any previous editorial/referee comments and how these have been dealt with as part of the appraisal process. If your manuscript is considered unsuitable for the journal to which it has been submitted, it may be assessed for suitability for publication in other Adis journals by appropriate editors. However, it will not be progressed to external peer review for an alternative journal without your permission.

    External Peer Review: Peer reviewer identities are kept confidential, but author identities are known to the reviewers. Peer reviewers are asked to disclose potential conflicts of interests that may affect their ability to provide an unbiased review of an article. The majority of manuscripts will require some degree of revision following peer review before they can be accepted for publication. The final decision on acceptability for publication lies with the journal editor.

    Copy Editing: All accepted manuscripts are copy edited. This process addresses general publishing considerations, such as layout of tables and figures, housestyle and clarity of expression. Authors will receive proofs following editing for their approval and sign off. It should be noted that the responsibility for checking the technical accuracy and consistency of data within the article rests with the authors.

    ……

    更多详情:

    https://www.springer.com/journal/40261/submission-guidelines



欢迎点评!让信息更透明,使投稿更轻松!
  • 审稿时间:
    是否录用:
  • 见刊周期:
    查重要求:
  • 有无课题:
    有无回复:
  • 我的学历:
    我的职称:
  • 审稿费用:
    版面费用:
  • 稿       费:
    稿件字数:
  • 投稿难度:
  • 该刊可发:
  • 投稿主题:
匿名: 验证码: 点击切换验证码
    评分:0

    验证码: 点击切换验证码